Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OK › Tulsa › NPI 1437657590
Physician

Advanced Pain Management Center of Oklahoma, LLC

Advanced Pain Management Center of Oklahoma, LLC was paid $2.23M by Medicaid between Oct 2021 and Nov 2024, across 23 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 36% of everything it billed.

33Billing provider infoADVANCED PAIN MANAGEMENT CENTER OF OKLAHOMA, LLC
TULSA, OK 74135
33aNPI1437657590assigned 01/24/2018
28Total paid$2.23M
24GClaims32,497
24DCodes billed23
24AFirst – last monthOct 2021 – Nov 2024
Compared with peers

Next to other Pain Medicine (Anesthesiology) Physician providers in Oklahoma

Rank by total paid#4 of 19
Median peer was paid$368K
This provider vs. median6.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$50K$100K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20212,407$162K
202210,173$797K
202311,861$859K
2024incomplete8,056$411K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 36% 10,640 10,144 $813K
64483 13% 1,792 1,788 $293K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 8.2% 3,700 3,511 $184K
64635 7.6% 474 474 $169K
64636 7.3% 421 419 $162K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 6.4% 2,625 2,562 $142K
62321 4.3% 575 574 $95K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 4.3% 839 839 $95K
99152 3.7% 2,572 2,559 $82K
64484 2.7% 882 879 $60K
64493 1.6% 210 204 $37K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.3% 291 289 $29K
11 more codes
64494 <1% 202 $19K
20610 <1% 332 $12K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 2,140 $10K
77002 <1% 141 $9K
27096 <1% 51 $6K
64495 <1% 39 $5K
62323 <1% 29 $4K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 2,763 $2K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 1,223 $494.30
J3010 Injection, fentanyl citrate, 0.1 mg <1% 374 $238.91
J2704 Injection, propofol, 10 mg <1% 182 $5.40

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSALGUERO, ALESHA (CEO)